<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9880">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00711100</url>
  </required_header>
  <id_info>
    <org_study_id>1R01CA135884</org_study_id>
    <secondary_id>1R01CA135884</secondary_id>
    <secondary_id>Study 1</secondary_id>
    <nct_id>NCT00711100</nct_id>
  </id_info>
  <brief_title>Evaluation of Oral Tobacco as a Harm Reduction Method for Smokers</brief_title>
  <official_title>Study 1: Preference, Health Effects and Efficacy of Four Oral Tobacco Products for Smoking Cessation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota - Clinical and Translational Science Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Minnesota - Clinical and Translational Science Institute</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recently, tobacco companies have developed new oral tobacco products that are purportedly
      less harmful than conventional tobacco products. These products have not been tested by
      independent research for their health effects or consumer palatability. In addition, it is
      not known if these products will be used in addition to cigarette smoking or as a substitute
      to cigarettes. These two studies will examine four oral tobacco products to answer some of
      these questions.

      The goals of this first study will be to examine: 1) the brand of oral tobacco products
      which is preferred by cigarette smokers and the pattern and amount of product use when used
      as a switching tool; 2) the characteristics that are associated with product choice; 3)
      nicotine exposure from these products; and 4) the withdrawal symptoms from the tobacco
      products and potential for continued use.

      Specifically, our primary aims hypotheses were: 1) the product that will be chosen by most
      smokers will be based on taste and sensory aspects of the product with products higher in
      nicotine content more likely to be chosen as the preferred product; and 2) subjects will
      experience no difficulty using the product for cessation, but a small minority will engage
      in dual product use.

      For the secondary aims, we hypothesized: 1) that compared to the subjects' own brand of
      cigarettes, the biomarkers for exposure for the oral tobacco products will be significantly
      lower; 2) withdrawal symptoms from the oral products are likely to occur, but are likely to
      be mild compared to cigarette withdrawal.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be accomplished by allowing subjects to sample the products and choose one
      oral tobacco product that they will use instead of cigarettes for a two week period. After
      the two weeks, they will discontinue all tobacco use and withdrawal symptoms and abstinence
      rates will be observed.

      Subjects will attend an orientation visit where the study will be explained in detail.
      Interested subjects will sign a consent form and be scheduled to return for baseline
      measures. Subjects will have a review of medical history to verify that they are in
      generally good health and do not have contraindications to the study products. Eligible
      subjects will collect one week of baseline measures while smoking at their normal rate:
      measures include daily diaries of smoking, questionnaires and urine samples. At the second
      baseline visit, they will receive samples of the oral tobacco products. The tobacco products
      tested are five novel oral products recently introduced to the market: 1) Camel Snus (higher
      nicotine); 2) General Snus (higher nicotine); 3) Marlboro Snus (lower nicotine); and two
      compressed tobacco tablets, 4) Ariva (lower nicotine), or 5) Stonewall (higher nicotine).
      All of these tobacco products are purported to have reduced levels of tobacco-specific
      nitrosamines.

      During sample weeks, subjects will be given 10 pouches/tablets of each product in a
      within-subject design and instructed to use at least three of the daily products in the
      morning of sample day and resume smoking in the afternoon and through the following day.
      They will sample the next product in a similar manner. The order of product was randomized.
      This design will allow a short, but adequate trial of each product to determine preference.
      After the sampling weeks, subjects will choose the product they will want to use to quit
      smoking. They will be supplied that product over the next two weeks.

      During the two weeks of product use during smoking cessation, subjects will come to weekly
      clinic visits and then a follow-up visits at 1 week and a phone call at 4 weeks after the
      end of treatment. At baseline, and 2 weeks post cigarette cessation, subjects will bring in
      a urine sample from their first morning void and bloods will be drawn. These samples will be
      analyzed for cotinine. At each visit, subjects will have vital signs obtained (blood
      pressure, heart rate, weight and carbon monoxide level), they will complete several
      subjective forms regarding tobacco use, withdrawal symptoms, and mood. Subjects will receive
      brief behavioral counseling for smoking cessation at all visits.

      In addition, during the sample weeks and at the end of two weeks of study product use,
      subjects will submit three used chews that will be sent to CDC to be analyzed for the
      tobacco constituents.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Product Preference</measure>
    <time_frame>2 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of individuals who selected each of the products (e.g., Camel Snus, Marlboro Snus, General Snus, Ariva, Stonewall).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Smoking Cessation</measure>
    <time_frame>2 and 4 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Nicotine Levels</measure>
    <time_frame>2 weeks on product</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">104</enrollment>
  <condition>Tobacco Use Disorder</condition>
  <arm_group>
    <arm_group_label>Camel Snus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Camel Snus (oral smokeless tobacco product) Dosage: 1.74-1.97 mg nicotine per portion; Frequency: Sampling period involves at least 3 samples, Intervention period involves daily use; Duration: Sampling period at least half a day, intervention period 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Marlboro Snus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Marlboro Snus (oral smokeless tobacco product) Dosage: 0.14 - 0.38 mg nicotine per portion; Frequency: Sampling period involves at least 3 samples, Intervention period involves daily use; Duration: Sampling period at least half a day, intervention period 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stonewall</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stonewall (oral dissolvable tobacco product) Dosage: 0.28-0.57 mg nicotine per portion; Frequency: Sampling period involves at least 3 samples, Intervention period involves daily use; Duration: Sampling period at least half a day, intervention period 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ariva</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ariva (oral dissolvable tobacco product) Dosage: 0.24-0.25 mg nicotine per portion; Frequency: Sampling period involves at least 3 samples, Intervention period involves daily use; Duration: Sampling period at least half a day, intervention period 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>General Snus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>General Snus (oral smokeless tobacco product); Dosage: 3.37 mg nicotine Frequency: Sampling period involves at least 3 samples, Intervention period involves daily use; Duration: Sampling period at least half a day, intervention period 2 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Camel Snus</intervention_name>
    <description>Subjects will sample each product for 1/2 day and choose one product to use for smoking cessation.</description>
    <arm_group_label>Camel Snus</arm_group_label>
    <arm_group_label>Marlboro Snus</arm_group_label>
    <arm_group_label>Stonewall</arm_group_label>
    <arm_group_label>Ariva</arm_group_label>
    <arm_group_label>General Snus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Marlboro Snus</intervention_name>
    <arm_group_label>Camel Snus</arm_group_label>
    <arm_group_label>Marlboro Snus</arm_group_label>
    <arm_group_label>Stonewall</arm_group_label>
    <arm_group_label>Ariva</arm_group_label>
    <arm_group_label>General Snus</arm_group_label>
    <other_name>Marlboor Snus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Stonewall</intervention_name>
    <arm_group_label>Camel Snus</arm_group_label>
    <arm_group_label>Marlboro Snus</arm_group_label>
    <arm_group_label>Stonewall</arm_group_label>
    <arm_group_label>Ariva</arm_group_label>
    <arm_group_label>General Snus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Ariva</intervention_name>
    <arm_group_label>Camel Snus</arm_group_label>
    <arm_group_label>Marlboro Snus</arm_group_label>
    <arm_group_label>Stonewall</arm_group_label>
    <arm_group_label>Ariva</arm_group_label>
    <arm_group_label>General Snus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>General Snus</intervention_name>
    <arm_group_label>Camel Snus</arm_group_label>
    <arm_group_label>Marlboro Snus</arm_group_label>
    <arm_group_label>Stonewall</arm_group_label>
    <arm_group_label>Ariva</arm_group_label>
    <arm_group_label>General Snus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cigarette smokers who smoke 10 or more cigarettes per day

          -  Generally good health

        Exclusion Criteria:

          -  Unstable medical or psychiatric condition.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dorothy Hatsukami, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota - Clinical and Translational Science Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Univeristy of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Research Institute</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>47404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <lastchanged_date>August 14, 2015</lastchanged_date>
  <firstreceived_date>July 2, 2008</firstreceived_date>
  <firstreceived_results_date>October 17, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Smoking cessation</keyword>
  <keyword>Oral tobacco products</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited 10/2008 through 8/2009 through local advertisements in Minnesota and Oregon.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Oral Tobacco Products</title>
          <description>Camel Snus, Marlboro Snus, General Snus, Stonewall, Ariva</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="104"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="91"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Oral Tobacco Products</title>
          <description>Camel Snus, Marlboro Snus, General Snus, Stonewall, Ariva</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="104"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="97"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="5"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="40.1" spread="13.2"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="40"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="64"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="104"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Product Preference</title>
        <description>Number of individuals who selected each of the products (e.g., Camel Snus, Marlboro Snus, General Snus, Ariva, Stonewall).</description>
        <time_frame>2 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Camel Snus</title>
            <description>Number of participants that sampled</description>
          </group>
          <group group_id="O2">
            <title>Marlboro Snus</title>
            <description>Number of particpants that sampled Marlboro Snus</description>
          </group>
          <group group_id="O3">
            <title>Stonewall</title>
            <description>Number of particpants that sampled Stonewall</description>
          </group>
          <group group_id="O4">
            <title>Ariva</title>
            <description>Number of particpants that sampled Ariva</description>
          </group>
          <group group_id="O5">
            <title>General Snus</title>
            <description>Number of particpants that sampled General Snus</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="98"/>
                  <measurement group_id="O2" value="98"/>
                  <measurement group_id="O3" value="98"/>
                  <measurement group_id="O4" value="98"/>
                  <measurement group_id="O5" value="98"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Product Preference</title>
            <description>Number of individuals who selected each of the products (e.g., Camel Snus, Marlboro Snus, General Snus, Ariva, Stonewall).</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="27"/>
                  <measurement group_id="O2" value="23"/>
                  <measurement group_id="O3" value="24"/>
                  <measurement group_id="O4" value="24"/>
                  <measurement group_id="O5" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Smoking Cessation</title>
        <time_frame>2 and 4 weeks</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nicotine Levels</title>
        <time_frame>2 weeks on product</time_frame>
        <safety_issue>Yes</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Camel Snus</title>
          <description>Particpants that sampled Camel Snus</description>
        </group>
        <group group_id="E2">
          <title>Marlboro Snus</title>
          <description>Particpants that sampled Marlboro Snus</description>
        </group>
        <group group_id="E3">
          <title>Stonewall</title>
          <description>Particpants that sampled Stonewall</description>
        </group>
        <group group_id="E4">
          <title>Ariva</title>
          <description>Particpants that sampled Ariva</description>
        </group>
        <group group_id="E5">
          <title>General Snus</title>
          <description>General Snus</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="23" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="98"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Excessive Salivation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="98"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E5" events="14" subjects_affected="14" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Dizziness/Lightheadedness</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="98"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Sore Throat</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dorothy Hatsukami, Ph.D.</name_or_title>
      <organization>University_of_Minnesota</organization>
      <phone>612-626-2121</phone>
      <email>hatsu001@umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
